JGC
TCON

J. Goldman & Co’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

J. Goldman & Co’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-850
Closed -$1.66M – 313
2015
Q3 		$1.66M Buy
+850
New +$1.99M 0.14% 154

Other funds holding TCON

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.66B AUM 14.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

J. Goldman & Co's TCON Position: Q4 2015 in Review

J. Goldman & Co sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2015, closing a stake of 850 shares — an estimated $1.66M sold.

J. Goldman & Co first reported a position in TCON in Q3 2015 and held it in 1 quarter. The position peaked at $1.66M in Q3 2015. 23 funds tracked by Wall St. Rank hold TCON as of Q4 2015.

  • J. Goldman & Co reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • J. Goldman & Co sold 850 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2015, an estimated $1.66M.
  • J. Goldman & Co first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • J. Goldman & Co's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $1.66M in Q3 2015.
  • 23 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2015.

Based on J. Goldman & Co's 13F filing for Q4 2015, filed 10 Feb 2016.